Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of IP Cisplatin and IV Paclitaxel in Gynecologic Cancers
NCT00582205Phase 2Terminated
- Sponsor
- University of Oklahoma
- Start
- Jan 2006
- Primary completion
- Dec 2011
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132) in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC) and 1 more, sponsored by University of Oklahoma. Primary endpoint: Number of Patients Who Are Able to Receive 6 Cycles of Intraperitoneal Cisplatin Chemotherapy at 3 years. Started Jan 2006; status: terminated.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)uterine cancer
Beyond the preview
Go deeper on NCT00582205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00582205.